Mast Therapeutics (MSTX) Reports Vepoloxamer Phase 3 in Sickle Cell Missed Primary Endpoint
Tweet Send to a Friend
Mast Therapeutics, Inc. (NYSE: MSTX) reported top-line results from EPIC, a Phase 3 clinical study of its investigational new drug ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE